Literature DB >> 22836222

Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention.

John A Eisman1, Earl R Bogoch, Rick Dell, J Timothy Harrington, Ross E McKinney, Alastair McLellan, Paul J Mitchell, Stuart Silverman, Rick Singleton, Ethel Siris.   

Abstract

Fragility fractures are common, affecting almost one in two older women and one in three older men. Every fragility fracture signals increased risk of future fractures as well as risk of premature mortality. Despite the major health care impact worldwide, currently there are few systems in place to identify and "capture" individuals after a fragility fracture to ensure appropriate assessment and treatment (according to national guidelines) to reduce future fracture risk and adverse health outcomes. The Task Force reviewed the current evidence about different systematic interventional approaches, their logical background, as well as the medical and ethical rationale. This included reviewing the evidence supporting cost-effective interventions and developing a toolkit for reducing secondary fracture incidence. This report presents this evidence for cost-effective interventions versus the human and health care costs associated with the failure to address further fractures. In particular, it summarizes the evidence for various forms of Fracture Liaison Service as the most effective intervention for secondary fracture prevention. It also summarizes the evidence that certain interventions, particularly those based on patient and/or community-focused educational approaches, are consistently, if unexpectedly, ineffective. As an international group, representing 36 countries throughout Asia-Pacific, South America, Europe, and North America, the Task Force reviewed and summarized the international data on barriers encountered in implementing risk-reduction strategies. It presents the ethical imperatives for providing quality of care in osteoporosis management. As part of an implementation strategy, it describes both the quality improvement methods best suited to transforming care and the research questions that remain outstanding. The overarching outcome of the Task Force's work has been the provision of a rational background and the scientific evidence underpinning secondary fracture prevention and stresses the utility of one form or another of a Fracture Liaison Service in achieving those quality outcomes worldwide. © 2012 American Society for Bone and Mineral Research.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Year:  2012        PMID: 22836222     DOI: 10.1002/jbmr.1698

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  132 in total

Review 1.  Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.

Authors:  T Saito; J M Sterbenz; S Malay; L Zhong; M P MacEachern; K C Chung
Journal:  Osteoporos Int       Date:  2017-08-02       Impact factor: 4.507

Review 2.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

Review 3.  Fracture Liaison Services in an open system: how was it done? what were the barriers and how were they overcome?

Authors:  Manju Chandran
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

4.  Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.

Authors:  Seoyoung C Kim; Mi-Sook Kim; Gabriel Sanfélix-Gimeno; Hong Ji Song; Jun Liu; Isabel Hurtado; Salvador Peiró; Joongyub Lee; Nam-Kyong Choi; Byung-Joo Park; Jerry Avorn
Journal:  Am J Med       Date:  2015-02-03       Impact factor: 4.965

Review 5.  Fracture liaison services: do they reduce fracture rates?

Authors:  Irma J A de Bruin; Caroline E Wyers; Joop P W van den Bergh; Piet P M M Geusens
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-04-27       Impact factor: 5.346

6.  The American Orthopaedic Association's Own the Bone® database: a national quality improvement project for the treatment of bone health in fragility fracture patients.

Authors:  B C Carlson; W A Robinson; N R Wanderman; A N Nassr; P M Huddleston; M J Yaszemski; B L Currier; K J Jeray; K L Kirk; A D Bunta; S Murphy; B Patel; C M Watkins; D L Sietsema; B J Edwards; L L Tosi; P A Anderson; B A Freedman
Journal:  Osteoporos Int       Date:  2018-06-01       Impact factor: 4.507

7.  Implementation of the Western Australian Osteoporosis Model of Care: a fracture liaison service utilising emergency department information systems to identify patients with fragility fracture to improve current practice and reduce re-fracture rates: a 12-month analysis.

Authors:  C A Inderjeeth; W D Raymond; A M Briggs; E Geelhoed; D Oldham; D Mountain
Journal:  Osteoporos Int       Date:  2018-04-27       Impact factor: 4.507

8.  Second fractures among older adults in the year following hip, shoulder, or wrist fracture.

Authors:  J P W Bynum; J-E Bell; R V Cantu; Q Wang; C M McDonough; D Carmichael; T D Tosteson; A N A Tosteson
Journal:  Osteoporos Int       Date:  2016-02-24       Impact factor: 4.507

9.  Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010.

Authors:  Stephen K Liu; Jeffrey C Munson; John-Erik Bell; Rebecca L Zaha; John N Mecchella; Anna N A Tosteson; Nancy E Morden
Journal:  J Am Geriatr Soc       Date:  2013-10-28       Impact factor: 5.562

10.  Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.

Authors:  K Moriwaki; S Noto
Journal:  Osteoporos Int       Date:  2016-10-04       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.